National Cohort of Compassionate Use of Meropenem-Vaborbactam: No Benefit over Meropenem for Pseudomonas aeruginosa.
Dinh A, Bleibtreu A, Duran C, Bouchand F, Bosch A, Crozon-Clauzel J, Roncato-Saberan M, Matt M, Boibieux A, Fanton A, Wille H, Fiaux E, Pilmis B, Lacoste M, Saint-Genis Q, Thumerelle C, Pavese P, Vuotto F, Senneville E, Potron A, Corvec S, Boutoille D, Jeannot K, Dortet L, On Behalf Of The Meropenem-Vaborbactam French Study Group.
Dinh A, et al. Among authors: bosch a.
Antibiotics (Basel). 2024 Dec 1;13(12):1152. doi: 10.3390/antibiotics13121152.
Antibiotics (Basel). 2024.
PMID: 39766541
Free PMC article.